Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 in Advanced KRAS G12D Mutant Solid Tumors
NCT05533463Phase 1Active, not recruiting
- Sponsor
- Hengrui
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-4642 in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoints: Adverse Events and Serious Adverse Events at 24 months, Dose Limiting Toxicity and 2 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
HRS-4642
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05533463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533463.